{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:59:36Z","timestamp":1783468776366,"version":"3.55.0"},"reference-count":40,"publisher":"Termedia Sp. z.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>Endometrial cancer is the\u00a0most common malignant neoplasm of\u00a0the\u00a0female reproductive system. The number of\u00a0diagnosed cases is increasing every year. In recent years, the\u00a0triple-negative phenomenon (TNP) has been identified as one of\u00a0the\u00a0determinants of\u00a0shorter survival in endometrial cancer patients. The aim of\u00a0the\u00a0study was to compare the\u00a0PARP-1 protein expression in triple-negative (TNEC) and non-triple-negative (NTNEC) endometrial cancer patients and determine the\u00a0relationship between the\u00a0PARP-1 protein expression in endometrial cancer cells and patient\u2019s overall survival depending on the\u00a0adopted scale (H-SCORE &lt; 75, H-SCORE &lt; 50, Allred scale). &lt;br \/&gt;\nThe study involved 265 patients with histopathologically confirmed endometrial cancer. The patients were divided into 2 groups: patients with TNEC and patients with NTNEC. The study was conducted using a\u00a0tissue microarray technique. Expression of\u00a0PARP-1 protein was determined by immunohistochemistry. &lt;br \/&gt;\nProtein expression evaluation was performed using virtual microscopy and the\u00a0Image Scope computer image analysis system. &lt;br \/&gt;\nThe following conclusions were reached: total and individual levels of\u00a0nuclear or cytoplasmic PARP-1 expression varied with the\u00a0presence or absence of\u00a0TNP, and PARP-1 nuclear expression at the\u00a02+ level had a\u00a0significant effect on the\u00a0increased risk of\u00a0death (according to H-SCORE &lt; 75).<\/jats:p>","DOI":"10.5114\/pjp.2022.125613","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T03:53:01Z","timestamp":1678333981000},"page":"330-337","source":"Crossref","is-referenced-by-count":1,"title":["Immunohistochemical expression of\u00a0PARP-1 in triple-negative endometrial cancer \u2013 a\u00a0comparison of\u00a0different score systems"],"prefix":"10.5114","volume":"73","author":[{"given":"Micha\u0142","family":"Bulsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia Romana","family":"Jankowska-Szab\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Urasi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"ref-1692620","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan Estimates of\u00a0incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021; 0: 1-41.","DOI":"10.3322\/caac.21660"},{"key":"ref-1692621","unstructured":"Kilia\u00f1ska ZM, \u00afo\u00b3nierczyk J, W\u00easierska-G\u00b9dek J. Biologiczna aktywno\u0153\u00e6 polimerazy poli(ADP-rybozy)-1. Post Hig Med Dosw 2010; 64: 344-363."},{"key":"ref-1692622","doi-asserted-by":"crossref","unstructured":"Bian X, Gao J, Luo F, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 2018; 37: 341-351.","DOI":"10.1038\/onc.2017.326"},{"key":"ref-1692623","doi-asserted-by":"crossref","unstructured":"Philip CA, Laskov I, Beauchamp MC, et al. Inhibition of\u00a0PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer 2017; 8: 1-11.","DOI":"10.1186\/s12885-017-3639-0"},{"key":"ref-1692624","doi-asserted-by":"crossref","unstructured":"Ghabreau L, Roux JP, Frappart PO, et al. Poly(adp-ribose) polymerase-1, a\u00a0novel partner of\u00a0progesteron receptors in endometrial cancer and its precursors. Int J Cancer 2004; 109: 317-321.","DOI":"10.1002\/ijc.11731"},{"key":"ref-1692625","doi-asserted-by":"crossref","unstructured":"Janzen DM, Paik DY, Rosales MA, et al. Low levels of\u00a0circulating estrogen sensitize PTEN-null endometrial tumors to poly(ADP-ribose) polymerase (PARP) inhibition in vivo. Mol Cancer Ther 2013; 12: 2917-2928.","DOI":"10.1158\/1535-7163.MCT-13-0572"},{"key":"ref-1692626","doi-asserted-by":"crossref","unstructured":"Kothari R, Morrison C, Richardson D, et al. The prognostic significance of\u00a0the\u00a0triple negative phenotype in endometrial cancer. Gynecol Oncol 2010; 118: 172-175.","DOI":"10.1016\/j.ygyno.2010.04.015"},{"key":"ref-1692627","doi-asserted-by":"crossref","unstructured":"Voss MA, Gordon N, Maloney S, et al. Tetraspanin CD151 in a\u00a0novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 2011; 104: 1611-1618.","DOI":"10.1038\/bjc.2011.80"},{"key":"ref-1692628","doi-asserted-by":"crossref","unstructured":"Xue-Feng J, Qiong-Ian T, Xi-ming S, et al. Tumor-associated macrophages, epidermal growth factor receptor correlated with the\u00a0triple negative phenotype in endometrial endometrioid adenocarcinoma. Pathol Res Pract 2012; 208: 730-735.","DOI":"10.1016\/j.prp.2012.09.011"},{"key":"ref-1692629","unstructured":"Altundag O, Dursun P, Roach EC, et al. Triple negative endometrial cancer may be more sensitive to platinum based chemotherapy. J Buon 2013; 18: 289-295."},{"key":"ref-1692630","doi-asserted-by":"crossref","unstructured":"Porzio R, Cordini C, Rodolfi AM, et al. Triple negative endometrial cancer: incidence and prognosis in a\u00a0monoistitutional series of\u00a0220 patients. Oncol Lett 2020; 19: 2522-2526.","DOI":"10.3892\/ol.2020.11329"},{"key":"ref-1692631","doi-asserted-by":"crossref","unstructured":"Bulsa M, Urasi\u00f1ska E. Triple negative endometrial cancer. Ginekol Pol 2017; 88: 212-214.","DOI":"10.5603\/GP.a2017.0040"},{"key":"ref-1692632","unstructured":"McCarty KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of\u00a0biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721."},{"key":"ref-1692633","doi-asserted-by":"crossref","unstructured":"Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of\u00a0estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a\u00a0gynecologic oncology group study. Gynecol Oncol 2007; 106: 325-333.","DOI":"10.1016\/j.ygyno.2007.03.042"},{"key":"ref-1692634","doi-asserted-by":"crossref","unstructured":"Thinke AA, Chang MJ, Fook-Chong S, et al. Immunohistochemical expression of\u00a0hormone receptors in invasive breast carcinoma: correlation of\u00a0results of\u00a0H-SCORE with pathological parameters. Pathology 2001; 33: 21-25.","DOI":"10.1080\/00313020123290"},{"key":"ref-1692635","unstructured":"Allred D, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168."},{"key":"ref-1692636","doi-asserted-by":"crossref","unstructured":"Gottwald L, Kubiak R, Pasz-Walczak G, et al. The value of\u00a0progesterone and estrogen receptors expression in tissue microarray method in prognosis of\u00a0patients with endometrioid endometrial cancer. Ginekol Pol 2013; 84: 95-101.","DOI":"10.17772\/gp\/1602"},{"key":"ref-1692637","doi-asserted-by":"crossref","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of\u00a0Clinical Oncology\/College of\u00a0American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018; 36: 2105-2122.","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"ref-1692638","doi-asserted-by":"crossref","unstructured":"Bulsa M, Urasi\u00f1ska E. Triple negative phenomenon in endometrial cancer: recognition criteria and impact on survival. Ginekol Pol 2021.","DOI":"10.5603\/GP.a2021.0082"},{"key":"ref-1692639","doi-asserted-by":"crossref","unstructured":"Bryant HE, Schiltz N, Thomas HD, et al. Specific killing of\u00a0BRCA2-deficient tumours with inhibitors of\u00a0polu(ADP- ribose) polymerase. Nature 2005; 434: 913-917.","DOI":"10.1038\/nature03443"},{"key":"ref-1692640","doi-asserted-by":"crossref","unstructured":"Mendes-Pereira AM, Martin SA, Brough R, et al. Sunthetic lethal targeting of\u00a0PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-322.","DOI":"10.1002\/emmm.200900041"},{"key":"ref-1692641","doi-asserted-by":"crossref","unstructured":"Magan N, Isaacs RJ, Stowell KM. Treatmet with the\u00a0PARP- inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells. Anticancer Drugs 2012; 23: 627-637.","DOI":"10.1097\/CAD.0b013e328350900f"},{"key":"ref-1692642","doi-asserted-by":"crossref","unstructured":"Dinkic C, Jahn F, Zygmunt M, et al. PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncol Lett 2017; 13: 2847-2851.","DOI":"10.3892\/ol.2017.5795"},{"key":"ref-1692643","doi-asserted-by":"crossref","unstructured":"Barreta A, Sarian LO, Ferracini AC, et al. Immunohistochemistry expression of\u00a0targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis. Hum Pathol 2019; 85: 72-81.","DOI":"10.1016\/j.humpath.2018.10.028"},{"key":"ref-1692644","doi-asserted-by":"crossref","unstructured":"Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of\u00a0Clinical Oncology\/College of\u00a0American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.","DOI":"10.1200\/JCO.2006.09.2775"},{"key":"ref-1692645","doi-asserted-by":"crossref","unstructured":"Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of\u00a0usual blood pressure to vascular mortality: a\u00a0meta- analysis of\u00a0individual data for one million adults in 61 prospective studies. Lancet 2002: 360: 1903-1913.","DOI":"10.1016\/S0140-6736(02)11911-8"},{"key":"ref-1692646","doi-asserted-by":"crossref","unstructured":"Jagielski L, Jele\u00f1 M, Kobierzycki C, et al. Increase of\u00a0nuclear expresion of\u00a0metallothionein I\/II in neoplastic transformation of\u00a0the\u00a0endometrium. Ginekol Pol 2015; 28: 182-187.","DOI":"10.17772\/gp\/2060"},{"key":"ref-1692647","doi-asserted-by":"crossref","unstructured":"El-Sharkawy SL, Abbas NF, El-Henawy AM, et al. Morphometric and DNA image analysis of\u00a0endometrial hyperplasia and carcinoma. Appl Immunohistochem Mol Morphol 2017; 25: 32-38.","DOI":"10.1097\/PAI.0000000000000259"},{"key":"ref-1692648","doi-asserted-by":"crossref","unstructured":"Elhafey AS, Papadimitriou JC, El-Hakim MS. Computerized image analysis of\u00a0p53 and proliferating cell nuclear antigen expression in benign, Hyperplastic, and malignant endometrium. Arch Pathol Lab Med 2001; 125: 872-879.","DOI":"10.5858\/2001-125-0872-CIAOPA"},{"key":"ref-1692649","doi-asserted-by":"crossref","unstructured":"Miller J, Geisler JP, Manahan KJ, et al. Nuclear size, shape, and density in endometrial carcinoma: relationship to survival at over 5 years of\u00a0follow-up. Does analyzing only cells occupying the\u00a0G0-G1 peak add useful information? Int J Gynecol Cancer 2004; 14: 138-144.","DOI":"10.1111\/j.1048-891x.2004.14031.x"},{"key":"ref-1692650","unstructured":"Sun H, Zeng X, Xu T, et al. Computer-aided diagnosis in histopathological images of\u00a0the\u00a0endometrium using a\u00a0convolutional neural network and attention mechanisms. J Biomed Health Inform 2019; 1: 1-10."},{"key":"ref-1692651","doi-asserted-by":"crossref","unstructured":"Graham A, Faratian D, Rae F, et al. Tissue microarray technology in the\u00a0routine assessment of\u00a0HER-2 status in invasive breast cancer: a\u00a0prospective study of\u00a0the\u00a0use of\u00a0immunohistochemistry and fluorescence in situ hybridization. Histopathology 2008; 52: 847-855.","DOI":"10.1111\/j.1365-2559.2008.03047.x"},{"key":"ref-1692652","doi-asserted-by":"crossref","unstructured":"Chen W, Foran D. Advances in cancer tissue microarray technology: towards improved understanding and diagnostics. Anal Chim Acta 2006; 30: 74-81.","DOI":"10.1016\/j.aca.2005.11.083"},{"key":"ref-1692653","doi-asserted-by":"crossref","unstructured":"Gulmann C, O\u2019Grady A. Tissue microarrays: an overview. Curr Diagn Pathol 2003; 9: 149-154.","DOI":"10.1016\/S0968-6053(02)00094-7"},{"key":"ref-1692654","doi-asserted-by":"crossref","unstructured":"Kononen J, Budendorf L, Kallioniemi OP, et al. Tissue microarrays for high-throughput molecular profiling of\u00a0tumor specimens. Nat Med 1998; 4: 844-847.","DOI":"10.1038\/nm0798-844"},{"key":"ref-1692655","doi-asserted-by":"crossref","unstructured":"Lugli A, Tornillo L, Mirlacher M, et al. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol 2004; 122: 721-727.","DOI":"10.1309\/KC09-YTF2-M4DL-UYQ6"},{"key":"ref-1692656","doi-asserted-by":"crossref","unstructured":"Ganceberg D, Di Leo A, Rouas G, et al. Reliability of\u00a0the\u00a0tissue microarray based FOSH for evaluation of\u00a0the\u00a0HER-2 oncogene in vreast carcinoma. J Clin Pathol 2002; 55: 315-317.","DOI":"10.1136\/jcp.55.4.315"},{"key":"ref-1692657","doi-asserted-by":"crossref","unstructured":"Chen W, Foran DJ. Advances in cancer tissue microarray technology: towards improved understanding and diagnostics. Anal Chim Acta 2006; 30: 74-81.","DOI":"10.1016\/j.aca.2005.11.083"},{"key":"ref-1692658","doi-asserted-by":"crossref","unstructured":"Visser N, van der Wurff A, Pijnenborg J, et al. Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer. Virchows Arch 2018; 472: 407-413.","DOI":"10.1007\/s00428-017-2289-6"},{"key":"ref-1692659","doi-asserted-by":"crossref","unstructured":"Peres G, Spadoto-Dias D, Bueloni-Dias F, et al. Immunohistochemical expression of\u00a0hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP-2 and -9 in endometrial polyps and endometrial cancer type I. Onco Targets Ther 2018; 11: 3949-3958.","DOI":"10.2147\/OTT.S160014"}],"container-title":["Polish Journal of Pathology"],"original-title":[],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-156640-136640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-156640-136640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:54:52Z","timestamp":1782212092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/Immunohistochemical-expression-of-PARP-1-in-triple-negative-endometrial-cancer-a,156640,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"alternative-id":["156640"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2022.125613","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}